Hospital
Hospital of Louisa, INC.
Hospital of Louisa, INC. was paid $27.77M by Medicaid between Jan 2018 and Dec 2024, across 217 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoHOSPITAL OF LOUISA, INC.
LOUISA, KY 41230
LOUISA, KY 41230
33aNPI1063484483assigned 02/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.77M
24GClaims650,949
24DCodes billed217
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#22 of 36
Median peer was paid$36.08M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,969 | $5.22M | |
| 2019 | 113,894 | $4.69M | |
| 2020 | 106,002 | $4.08M | |
| 2021 | 91,081 | $3.52M | |
| 2022 | 77,801 | $3.47M | |
| 2023 | 83,449 | $3.59M | |
| 2024incomplete | 61,753 | $3.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 21,824 | 16,516 | $4.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 29,831 | 22,395 | $4.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 12,935 | 6,288 | $3.75M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.3% | 7,108 | 5,046 | $1.19M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.2% | 3,601 | 2,316 | $1.17M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.8% | 2,402 | 1,440 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 3,607 | 2,442 | $800K |
| 71045 | Radiologic examination, chest; single view | 2.3% | 17,782 | 10,151 | $638K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 8,391 | 5,996 | $571K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 5,142 | 4,518 | $497K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 11,141 | 2,549 | $485K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 4,894 | 3,551 | $418K |
205 more codes
| 80053 | Comprehensive metabolic panel | 1.4% | 50,246 | $391K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 8,799 | $300K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 4,471 | $292K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 17,712 | $280K |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,963 | $269K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,360 | $257K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,412 | $236K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,867 | $229K |
| 87902 | <1% | 1,037 | $225K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,311 | $219K |
| G0378 | Hospital observation service, per hour | <1% | 2,974 | $203K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,221 | $200K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,355 | $196K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,541 | $191K |
| 91200 | <1% | 1,829 | $190K | |
| J3490 | Unclassified drugs | <1% | 24,788 | $185K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,945 | $183K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 921 | $175K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,038 | $159K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 643 | $150K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 529 | $144K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,286 | $130K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,158 | $124K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,697 | $122K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,605 | $112K |
| 73562 | <1% | 2,014 | $97K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,550 | $91K |
| 72131 | <1% | 865 | $84K | |
| 84484 | <1% | 9,268 | $80K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,488 | $80K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,176 | $77K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,905 | $77K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 152 | $76K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,951 | $71K |
| 80061 | Lipid panel | <1% | 5,887 | $70K |
| 86738 | <1% | 5,292 | $67K | |
| 85027 | <1% | 10,763 | $63K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,267 | $63K |
| 71250 | <1% | 598 | $62K | |
| 73630 | <1% | 2,110 | $62K | |
| 84703 | <1% | 7,591 | $59K | |
| 73610 | <1% | 1,922 | $58K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,207 | $56K |
| 73030 | <1% | 1,512 | $55K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 329 | $52K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,192 | $48K |
| 78264 | <1% | 270 | $47K | |
| 83690 | <1% | 6,841 | $46K | |
| 81001 | <1% | 12,144 | $46K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,623 | $45K |
| 84439 | <1% | 4,230 | $44K | |
| 73130 | <1% | 1,424 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,011 | $41K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,852 | $41K |
| 70486 | <1% | 235 | $40K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 246 | $40K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,082 | $38K |
| 82607 | <1% | 2,443 | $37K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,360 | $34K |
| 74018 | <1% | 953 | $33K | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 2,273 | $33K |
| 73110 | <1% | 985 | $32K | |
| 97161 | <1% | 564 | $31K | |
| 87040 | <1% | 3,244 | $30K | |
| 87186 | <1% | 3,101 | $29K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,384 | $28K |
| 80074 | <1% | 696 | $28K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,959 | $27K |
| 93017 | <1% | 290 | $26K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,904 | $26K |
| 85610 | <1% | 5,449 | $25K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,942 | $25K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,387 | $25K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,616 | $24K |
| 83735 | <1% | 3,803 | $24K | |
| 96376 | <1% | 2,035 | $23K | |
| 86317 | <1% | 1,534 | $22K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 773 | $22K |
| 82728 | <1% | 1,733 | $22K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,111 | $21K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,716 | $21K |
| 87088 | <1% | 2,400 | $19K | |
| 43249 | <1% | 15 | $19K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 1,304 | $18K |
| 82746 | <1% | 1,294 | $17K | |
| 87340 | <1% | 1,427 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,667 | $16K |
| 74021 | <1% | 559 | $16K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 232 | $16K |
| 76536 | <1% | 207 | $15K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 2,280 | $15K |
| 82553 | <1% | 1,003 | $15K | |
| 83880 | <1% | 1,029 | $14K | |
| 81003 | <1% | 4,640 | $14K | |
| 72100 | <1% | 315 | $14K | |
| 00731 | <1% | 196 | $13K | |
| 86708 | <1% | 1,214 | $13K | |
| 86704 | <1% | 1,179 | $13K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 973 | $12K |
| 86038 | <1% | 913 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,567 | $12K |
| 83540 | <1% | 1,893 | $12K | |
| 84520 | <1% | 1,369 | $11K | |
| 82962 | <1% | 3,843 | $11K | |
| 73080 | <1% | 220 | $11K | |
| 97010 | <1% | 1,889 | $11K | |
| 87517 | <1% | 334 | $11K | |
| 82550 | <1% | 1,267 | $11K | |
| 85379 | <1% | 1,602 | $11K | |
| 83550 | <1% | 1,121 | $10K | |
| 86140 | <1% | 1,898 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,228 | $9K |
| 87807 | <1% | 1,115 | $8K | |
| 85651 | <1% | 1,658 | $7K | |
| 83605 | <1% | 1,217 | $7K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 54 | $7K |
| 00813 | <1% | 57 | $7K | |
| 73090 | <1% | 204 | $6K | |
| 85730 | <1% | 1,376 | $6K | |
| 84403 | <1% | 214 | $5K | |
| 93226 | <1% | 38 | $5K | |
| 73590 | <1% | 210 | $5K | |
| 92523 | <1% | 40 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 73 | $5K |
| 84550 | <1% | 166 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 138 | $4K |
| 87070 | <1% | 577 | $4K | |
| 82565 | <1% | 1,402 | $4K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 304 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 95 | $4K |
| 85007 | <1% | 2,525 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 481 | $3K |
| 93971 | <1% | 53 | $3K | |
| 97164 | <1% | 110 | $3K | |
| 77080 | <1% | 52 | $3K | |
| 94761 | <1% | 676 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 82 | $3K |
| 82805 | <1% | 178 | $3K | |
| 76775 | <1% | 48 | $3K | |
| 86707 | <1% | 314 | $3K | |
| 82150 | <1% | 291 | $3K | |
| 72192 | <1% | 14 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 16 | $3K |
| 87350 | <1% | 298 | $3K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 25 | $2K |
| 10060 | <1% | 15 | $2K | |
| 84402 | <1% | 98 | $2K | |
| 83970 | <1% | 59 | $2K | |
| 00811 | <1% | 33 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 378 | $2K |
| 73560 | <1% | 29 | $2K | |
| 93225 | <1% | 45 | $2K | |
| 73502 | <1% | 57 | $2K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 138 | $2K |
| 87493 | <1% | 42 | $1K | |
| 87205 | <1% | 136 | $1K | |
| 84702 | <1% | 75 | $822.74 | |
| 86800 | <1% | 48 | $808.86 | |
| 80050 | General health panel | <1% | 98 | $807.49 |
| 86376 | <1% | 61 | $781.20 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 23 | $717.19 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 812 | $700.31 |
| 82043 | <1% | 93 | $689.83 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 40 | $582.30 |
| 90686 | <1% | 48 | $553.62 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 160 | $518.02 |
| 36600 | <1% | 195 | $514.27 | |
| 82375 | <1% | 178 | $512.03 | |
| 86803 | <1% | 42 | $510.01 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $507.08 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 16 | $469.05 |
| 84466 | <1% | 43 | $468.41 | |
| 86308 | <1% | 17 | $463.82 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 20 | $406.66 |
| 96367 | <1% | 14 | $374.80 | |
| 86618 | <1% | 28 | $370.34 | |
| 86592 | <1% | 55 | $319.71 | |
| 89055 | <1% | 41 | $312.92 | |
| 90714 | <1% | 58 | $302.01 | |
| 87449 | <1% | 29 | $300.76 | |
| 83050 | <1% | 174 | $293.54 | |
| 84100 | <1% | 96 | $292.10 | |
| 87324 | <1% | 31 | $276.80 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 54 | $274.96 |
| 86021 | <1% | 17 | $226.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 75 | $184.04 |
| 82310 | <1% | 30 | $176.30 | |
| 94664 | <1% | 157 | $153.73 | |
| 82272 | <1% | 82 | $142.14 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 46 | $130.02 |
| 85018 | <1% | 206 | $128.02 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 54 | $127.11 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $114.75 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 34 | $109.31 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 25 | $99.64 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 82 | $98.61 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 54 | $91.98 |
| 87045 | <1% | 16 | $88.21 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $83.81 |
| 94760 | <1% | 40 | $62.63 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 34 | $42.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 13 | $37.20 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 28 | $13.46 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 13 | $12.77 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,508 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OP/AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.